Skip to content

9 Meters Biopharma, Inc.: 10-K filed 2019-03-18

What 9 Meters Biopharma, Inc. reported in its annual report filed 2019-03-18 (fiscal FY 2018): 33 published measures, 83 facts as tagged in accession 0001551986-19-000019.

This filing

Form
10-K (annual report)
Filed
2019-03-18
Fiscal period
fiscal FY 2018
Accession
0001551986-19-000019 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All 9 Meters Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-12-316,454,188USD
At 2017-12-31798,489USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-12-31-3,659,064USD
At 2017-12-31-12,174,614USD
At 2016-12-31-6,587,554USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-12-315,728,900USD
At 2017-12-31355,563USD
At 2016-12-31360,811USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-24,162,279USD365
2018-01-01 to 2018-09-30-19,951,226USD273
2018-01-01 to 2018-06-30-19,175,296USD181
2018-01-01 to 2018-03-31-14,959,744USD90
2017-01-01 to 2017-12-31-11,605,817USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-15,169,330USD365
2017-01-01 to 2017-12-31-5,096,546USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-01-01 to 2018-12-3113,943USD365
2017-01-01 to 2017-12-3138,727USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-01-01 to 2018-12-3120,556,610USD365
2017-01-01 to 2017-12-315,130,025USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-13,943USD365
2017-01-01 to 2017-12-31-38,727USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-12-31-43,515,970USD
At 2018-09-30-39,304,917USD
At 2018-06-30-38,528,987USD
At 2018-03-31-34,313,435USD
At 2017-12-31-19,353,691USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-12-3135,095USD
At 2017-12-3140,707USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-01-01 to 2018-12-313,805,000USD365
2017-01-01 to 2017-12-316,018,732USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-3118,224,068USD365
2018-01-01 to 2018-09-3014,485,035USD273
2018-01-01 to 2018-06-3014,704,688USD181
2018-01-01 to 2018-03-3111,328,617USD90
2017-01-01 to 2017-12-3111,169,523USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-12-316,413,513USD
At 2017-12-31752,202USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-01-01 to 2018-12-316,152,043USD365
2017-01-01 to 2017-12-31436,294USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-12-3110,113,252USD
At 2017-12-3112,973,103USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-12-313,618,634USD
At 2017-12-312,658,637USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-01-01 to 2018-12-3118,224,068USD365
2017-01-01 to 2017-12-3111,169,523USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-01-01 to 2018-12-317,559,077USD365
2017-01-01 to 2017-12-314,007,911USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-12-3126,088,820shares
At 2017-12-3111,888,240shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-12-3139,854,297USD
At 2018-09-3039,683,119USD
At 2018-06-3041,985,593USD
At 2018-03-3142,157,122USD
At 2017-12-317,167,189USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-12-3161,243USD
At 2017-12-3147,300USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-12-3126,148USD
At 2017-12-316,593USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-12-315,580USD
At 2017-12-315,580USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-12-31826,327USD
At 2017-12-311,180,225USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-12-31504,907USD
At 2017-12-31161,844USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-24,162,279USD365
2017-01-01 to 2017-12-31-11,605,817USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-01-01 to 2018-12-3110,664,991USD365
2018-01-01 to 2018-09-304,619,580USD273
2018-01-01 to 2018-06-306,405,225USD181
2018-01-01 to 2018-03-315,162,004USD90
2017-01-01 to 2017-12-317,161,612USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2018-01-01 to 2018-12-3119,555USD365
2017-01-01 to 2017-12-315,787USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2018-01-01 to 2018-12-31-5,938,211USD365
2017-01-01 to 2017-12-31-436,294USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-01-01 to 2018-12-31280,287USD365
2017-01-01 to 2017-12-310USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2018-01-01 to 2018-12-3118,132,661USD365
2017-01-01 to 2017-12-310USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-01-01 to 2018-12-3186,412USD365
2017-01-01 to 2017-12-31746,797USD365

Inspect the source

Entity
9 Meters Biopharma, Inc. / CIK 0001551986
Captured
SEC response SHA-256
59d642aec339d0632a0e624932e840a466f1b38d6bf6e39062c538e5ae599884

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001551986.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))